25 July 2016 - Significant step towards bringing the only licensed prescription medication for IBS-D to patients in 28 countries of the European Union.

Allergan today announced that the CHMP has adopted a positive opinion for Truberzi (eluxadoline) in the European Union. Truberzi is an oral medication that relieves the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults. In two pivotal trials, Truberzi significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and diarrhoea, with sustained relief demonstrated over six months. Truberzi was generally well tolerated with the most common side effects being nausea, constipation, and abdominal pain.

Read Allergan press release